Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

This study has been completed.
Sponsor:
Collaborator:
Trimeris
Information provided by:
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00002239
First received: November 2, 1999
Last updated: November 14, 2005
Last verified: November 2005

November 2, 1999
November 14, 2005
May 1999
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00002239 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
A Controlled Phase 2 Trial Assessing Three Doses of T-20 in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz in HIV-1 Infected Adults

The purpose of this study is to see if it is safe and effective to give T-20, a new type of anti-HIV drug, with a combination of other anti-HIV drugs. The other anti-HIV drugs used are abacavir (ABC), amprenavir (APV), ritonavir (RTV), and efavirenz (EFV). Three different doses of T-20 are tested.

Patients are assigned to one of four groups. Three dose groups receive a background antiretroviral regimen (ABC, APV, RTV, and EFV) and T-20, which is given at one of three doses on a twice-daily regimen. The fourth group (control) receives the background antiretroviral regimen alone. For each treatment group, 17 patients are enrolled. Treatment is administered for 16 weeks, followed by a 32-week treatment extension, and a 2-week follow-up period. The following are assessed throughout the trial: safety parameters (as measured by hematology, clinical chemistry, urinalysis, and treatment-emergent adverse events); virologic and immunologic activity; phenotypic and genotypic resistance; T-20 plasma levels; and pharmacokinetics of T-20 and oral antiretrovirals. The total study duration is 1 year.

Interventional
Phase 2
Endpoint Classification: Pharmacokinetics Study
Primary Purpose: Treatment
HIV Infections
  • Drug: Enfuvirtide
  • Drug: Ritonavir
  • Drug: Abacavir sulfate
  • Drug: Amprenavir
  • Drug: Efavirenz
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
68
Not Provided
Not Provided

Inclusion Criteria

Patients may be eligible for this study if they:

  • Are HIV-positive.
  • Have an HIV level (viral load) between 400 and 100,000 copies/ml at the screening visit.
  • Have taken at least 1 PI (protease inhibitor) for at least 16 weeks, and have had no interruptions in their most recent PI-containing anti-HIV drug regimen.
  • Are at least 18 years old.
  • Agree to abstinence or use of 2 effective methods of birth control, including a barrier method, during the study.

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have ever taken an NNRTI (nonnucleoside reverse transcriptase inhibitor).
  • Have an opportunistic (HIV-related) infection.
  • Have had an unexplained fever of at least 38.5 C for 7 days in a row within 30 days prior to screening.
  • Have had diarrhea lasting at least 15 days within 30 days prior to screening.
  • Have ever taken abacavir, amprenavir, or efavirenz (ABC, APV, or EFV).
  • Have certain genetic characteristics (drug resistance mutations) that could change the way a drug acts in the body.
  • Are allergic to any of the study medications.
  • Have a tumor other than certain skin or cervical cancers.
  • Are on chemotherapy that cannot be discontinued during the study.
  • Are taking an investigational drug within 30 days prior to screening.
  • Have ever received an HIV vaccine.
  • Are taking certain medications.
  • Abuse drugs or alcohol.
  • Have hemophilia or another blood clotting disorder.
  • Have had an organ transplant.
  • Are pregnant or breast-feeding.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00002239
T20-206, 295B
Not Provided
Not Provided
Hoffmann-La Roche
Trimeris
Not Provided
Hoffmann-La Roche
November 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP